ArticleDermatology and therapy2025
Prevalence and Trends in Systemic Treatment for Pediatric Psoriasis in the USA between 2015 and 2021.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBiologics may have altered the standard of care for pediatric psoriasis, the prevalence of which has not been studied since 2015. The objective of this study was to provide an update of the prevalence of and treatment landscape for pediatric psoriasis in the USA, highlighting the current burden of the condition and the need for improved disease awareness.
methodsIn this retrospective cohort study, US claims data (July 2015 to October 2021) from the MarketScan
resultsA total of 8935 pediatric patients with psoriasis were included, of whom 1448 had moderate to severe psoriasis. In 2020, the estimated overall pediatric psoriasis prevalence based on coding was 117.4/100,000, and it was 18.4/100,000 for moderate to severe psoriasis. Between 2017 and 2021, the use of non-biologic systemic treatments (2017: 36.3/100 PY; 2021: 14.1/100 PY) and phototherapy treatments (2017: 41.3/100 PY; 2021: 4.3/100 PY) decreased, while the use of biologics increased (2017: 41.5/100 PY; 2021: 56.4/100 PY). Interleukin inhibitor use increased (2017: 5.0/100 PY; 2021: 37.6/100 PY), while tumor necrosis factor (TNF) inhibitor use decreased (2017: 37.5/100 PY; 2021: 20.2/100 PY). Ustekinumab use increased the most (2017: 4.8/100 PY; 2021: 30.4/100 PY), followed by ixekizumab (2017: 0.2/100 PY; 2021: 7.2/100 PY).
conclusionsIn 2020, psoriasis remained relatively uncommon among US children and adolescents, with 15.9% having moderate to severe psoriasis. Meanwhile, treatment for moderate to severe psoriasis shifted from older treatments, particularly non-biologic systemics and TNF inhibitors, toward newer, more efficacious interleukin inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.